JP2022526595A5 - - Google Patents

Info

Publication number
JP2022526595A5
JP2022526595A5 JP2021559093A JP2021559093A JP2022526595A5 JP 2022526595 A5 JP2022526595 A5 JP 2022526595A5 JP 2021559093 A JP2021559093 A JP 2021559093A JP 2021559093 A JP2021559093 A JP 2021559093A JP 2022526595 A5 JP2022526595 A5 JP 2022526595A5
Authority
JP
Japan
Prior art keywords
sequence
seq
variable region
triple
cdr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021559093A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022526595A (ja
JP7776987B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/026686 external-priority patent/WO2020206330A1/en
Publication of JP2022526595A publication Critical patent/JP2022526595A/ja
Publication of JP2022526595A5 publication Critical patent/JP2022526595A5/ja
Application granted granted Critical
Publication of JP7776987B2 publication Critical patent/JP7776987B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021559093A 2019-04-05 2020-04-03 Psmaに結合する重鎖抗体 Active JP7776987B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962830130P 2019-04-05 2019-04-05
US62/830,130 2019-04-05
PCT/US2020/026686 WO2020206330A1 (en) 2019-04-05 2020-04-03 Heavy chain antibodies binding to psma

Publications (3)

Publication Number Publication Date
JP2022526595A JP2022526595A (ja) 2022-05-25
JP2022526595A5 true JP2022526595A5 (cg-RX-API-DMAC7.html) 2023-04-10
JP7776987B2 JP7776987B2 (ja) 2025-11-27

Family

ID=70476405

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021559093A Active JP7776987B2 (ja) 2019-04-05 2020-04-03 Psmaに結合する重鎖抗体

Country Status (19)

Country Link
US (3) US12180298B2 (cg-RX-API-DMAC7.html)
EP (1) EP3947470A1 (cg-RX-API-DMAC7.html)
JP (1) JP7776987B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210149076A (cg-RX-API-DMAC7.html)
CN (1) CN113710707B (cg-RX-API-DMAC7.html)
AU (1) AU2020252556B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021019334A2 (cg-RX-API-DMAC7.html)
CA (1) CA3133654A1 (cg-RX-API-DMAC7.html)
CL (2) CL2021002586A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021013279A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210500A (cg-RX-API-DMAC7.html)
EA (1) EA202192736A1 (cg-RX-API-DMAC7.html)
IL (1) IL286398A (cg-RX-API-DMAC7.html)
JO (1) JOP20210253A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021012205A (cg-RX-API-DMAC7.html)
PE (1) PE20220142A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021552538A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202111027WA (cg-RX-API-DMAC7.html)
WO (1) WO2020206330A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL299221A (en) 2016-06-21 2023-02-01 Teneobio Inc Cd3 binding antibodies
CN109862784A (zh) 2016-08-24 2019-06-07 特尼奥生物股份有限公司 产生经修饰的仅有重链的抗体的转基因非人动物
CR20220578A (es) 2016-09-14 2023-01-17 Teneobio Inc Anticuerpos de unión a cd3
EP3559035A1 (en) 2016-12-21 2019-10-30 TeneoBio, Inc. Anti-bcma heavy chain-only antibodies
CN110891971B (zh) 2017-06-20 2024-01-12 特尼奥生物股份有限公司 仅有重链的抗bcma抗体
JP7240335B2 (ja) 2017-06-20 2023-03-15 テネオワン, インコーポレイテッド 抗bcma重鎖のみ抗体
EA202091557A1 (ru) 2017-12-22 2020-11-18 Тенеобио, Инк. Антитела, содержащие только тяжелые цепи, которые связываются с cd22
CA3133654A1 (en) 2019-04-05 2020-10-08 Teneobio, Inc. Heavy chain antibodies binding to psma
CN114206927B (zh) 2019-06-14 2025-03-21 特尼奥生物股份有限公司 与cd22和cd3结合的多特异性重链抗体
KR20250007022A (ko) 2020-04-29 2025-01-13 테네오원, 인코포레이티드 변형된 중쇄 불변 영역을 갖는 다중특이적 중쇄 항체
TWI815194B (zh) * 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
TW202233684A (zh) * 2020-11-18 2022-09-01 美商泰尼歐生物公司 結合於葉酸受體α之重鏈抗體
MX2023008909A (es) * 2021-01-28 2023-10-23 Janssen Biotech Inc Proteínas de unión a psma y usos de estas.
WO2022183074A2 (en) * 2021-02-25 2022-09-01 Teneobio, Inc. Anti-psma antibodies and car-t structures
CN117337303A (zh) * 2021-04-16 2024-01-02 特尼奥生物股份有限公司 抗cd20抗体及car-t结构
US20240209115A1 (en) 2021-04-29 2024-06-27 Amgen Inc. Methods for reducing low molecular weight species of recombinantly-produced proteins
WO2023183231A1 (en) 2022-03-21 2023-09-28 Amgen Inc. Combination therapy methods with t-cell engaging molecules for treatment of prostate cancer
CN119552258B (zh) * 2023-09-01 2025-11-07 北京智仁美博生物科技有限公司 结合hla-a02/mage-a4复合体的多种抗体及其用途

Family Cites Families (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US6750325B1 (en) 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5968509A (en) 1990-10-05 1999-10-19 Btp International Limited Antibodies with binding affinity for the CD3 antigen
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
CZ303272B6 (cs) 1999-01-07 2012-07-11 Zymogenetics, Inc. Farmaceutický prostredek obsahující fúzní protein, izolovaná molekula polynukleotidu, expresní vektor, kultivovaná bunka, zpusob prípravy polypeptidu a izolovaný polypeptid
HK1043608B (en) 1999-08-17 2007-12-07 Biogen Ma Inc. Baff receptor (bcma), an immunoregulatory agent
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
AU6232899A (en) 1999-10-06 2001-05-10 Campina Melkunie B.V. Use of transforming growth factor beta and growth factors in the treatment and prevention of diseases of the intestinal mucosa
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
AU2001263114A1 (en) 2000-05-12 2001-11-26 Amgen Inc Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
AU2002238052A1 (en) 2001-02-20 2002-09-04 Zymogenetics, Inc. Antibodies that bind both bcma and taci
CN1195779C (zh) 2001-05-24 2005-04-06 中国科学院遗传与发育生物学研究所 抗人卵巢癌抗人cd3双特异性抗体
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
MXPA05004677A (es) 2002-10-31 2005-11-17 Genentech Inc Metodos y composiciones para aumentar la produccion de anticuerpos.
WO2004065417A2 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
AU2004242846A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
NZ543202A (en) 2003-05-31 2008-04-30 Micromet Ag Pharmaceutical composition comprising a bispecific antibody for epcam
US8076459B2 (en) 2003-10-16 2011-12-13 Micromet Ag Multispecfic deimmunized CD3-binders
DK2383295T3 (en) 2003-12-10 2015-06-15 Squibb & Sons Llc Ip-10 antibodies and uses thereof
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
SG188175A1 (en) 2004-06-03 2013-03-28 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
EP1776383B1 (en) 2004-07-22 2014-08-20 Erasmus University Medical Center Rotterdam Binding molecules
US8207303B2 (en) 2005-02-18 2012-06-26 Medarex, Inc. Monoclonal antibodies against CD30 lacking in fucosyl residues
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
JP2008543839A (ja) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AU2006291005A1 (en) 2005-09-12 2007-03-22 Novimmune S.A. Anti-CD3 antibody formulations
US8236308B2 (en) 2005-10-11 2012-08-07 Micromet Ag Composition comprising cross-species-specific antibodies and uses thereof
CA2629306A1 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
US20100021473A1 (en) 2005-12-06 2010-01-28 Domantis Limited Bispecific Ligands With Binding Specificity to Cell Surface Targets and Methods of Use Therefor
WO2007117600A2 (en) 2006-04-07 2007-10-18 Macrogenics, Inc. Combination therapy for treating autoimmune diseases
WO2008016431A2 (en) 2006-07-29 2008-02-07 Robert Lamar Bjork Bi-specific monoclonal antibody (specific for both cd3 and cd11b) therapeutic drug
PL2155788T3 (pl) 2007-04-03 2013-02-28 Amgen Res Munich Gmbh Swoiste międzygatunkowe bispecyficzne czynniki wiążące
WO2008119567A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
WO2008119565A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific binding domain
KR101703299B1 (ko) 2007-06-01 2017-02-06 오픈 모노클로날 테크놀로지, 인코포레이티드 내생적 면역글로불린 유전자를 억제하고 트랜스제닉 인간 이디오타입 항체를 생산하기 위한 방법 및 조성물
CA2720682A1 (en) 2008-04-25 2009-10-29 Zymogenetics, Inc. Levels of bcma protein expression on b cells and use in diagnostic methods
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
WO2010032061A1 (en) 2008-09-19 2010-03-25 Medimmune Llc Antibodies against sonic hedgehog homolog and uses thereof
AU2009299794B2 (en) 2008-10-01 2015-08-13 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
MX2011003502A (es) 2008-10-01 2011-09-01 Micromet Ag Anticuerpo de cadena sencilla biespecifica de psmaxcd3 especifico a traves de especies.
KR101837053B1 (ko) 2008-10-01 2018-03-12 암젠 리서치 (뮌헨) 게엠베하 종간 특이적 PSCAxCD3, CD19xCD3, c-METxCD3, 엔도시알린xCD3, EpCAMxCD3, IGF-1RxCD3 또는 FAPαxCD3 이중특이적 단일쇄 항체
EP2352763B2 (en) 2008-10-01 2022-09-21 Amgen Research (Munich) GmbH Bispecific single chain antibodies with specificity for high molecular weight target antigens
CN102421801B (zh) 2009-03-10 2016-03-16 比奥根Ma公司 抗-bcma抗体
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
SG183149A1 (en) 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
TWI653333B (zh) 2010-04-01 2019-03-11 安進研究(慕尼黑)有限責任公司 跨物種專一性之PSMAxCD3雙專一性單鏈抗體
EP3974453A3 (en) 2010-11-16 2022-08-03 Amgen Inc. Agents and methods for treating diseases that correlate with bcma expression
WO2012122512A1 (en) 2011-03-10 2012-09-13 Hco Antibody, Inc. Recombinant production of mixtures of single chain antibodies
CN103619876A (zh) 2011-03-10 2014-03-05 Hco抗体股份有限公司 双特异性三链抗体样分子
US20130101599A1 (en) 2011-04-21 2013-04-25 Boehringer Ingelheim International Gmbh Bcma-based stratification and therapy for multiple myeloma patients
BR112013027224A8 (pt) 2011-04-22 2018-08-14 Emergent Product Dev Seattle Proteínas de ligação de antígeno de membrana específico de próstata e composições e métodos relacionados
EP2714737A1 (en) 2011-05-27 2014-04-09 Glaxo Group Limited Bcma (cd269/tnfrsf17) -binding proteins
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對bcma之e3以及cd3的結合分子
IN2014MN02293A (cg-RX-API-DMAC7.html) 2012-04-20 2015-08-07 Emergent Product Dev Seattle
BR112014032916A2 (pt) 2012-06-28 2017-08-01 Pfizer anticorpos anti-fármacos e usos destes para o monitoramento de fármaco
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
EP2914628A1 (en) 2012-11-01 2015-09-09 Max-Delbrück-Centrum für Molekulare Medizin An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Bcma抗原結合蛋白質
WO2014093908A2 (en) 2012-12-14 2014-06-19 Omt, Inc. Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
JP6636803B2 (ja) 2013-02-05 2020-01-29 エンクマフ エスアーエールエル Bcmaに対する抗体の選択のための方法
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
US10993420B2 (en) 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals
CA2904806C (en) 2013-04-29 2021-11-23 F. Hoffmann-La Roche Ag Human fcrn-binding modified antibodies and methods of use
MX373301B (es) 2013-10-31 2020-04-24 Sanofi Sa Anticuerpos anti-cd38 específicos para usarse para tratar cánceres humanos.
AP2016009222A0 (en) 2013-11-04 2016-05-31 Glenmark Pharmaceuticals Sa Production of t cell retargeting hetero-dimeric immunoglobulins
WO2015095412A1 (en) 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
EP3105252B1 (en) 2014-02-12 2019-07-24 Michael Uhlin Bispecific antibodies for use in stem cell transplantation
CA2935748A1 (en) 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
PL3122781T3 (pl) 2014-03-28 2020-06-15 Xencor, Inc. Dwuswoiste przeciwciała, które wiążą się z CD38 i CD3
AU2015292744C1 (en) 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
CA2955947A1 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
PL3209698T5 (pl) 2014-10-22 2022-04-25 Crescendo Biologics Limited Mysz transgeniczna
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
ES2808853T3 (es) 2014-11-20 2021-03-02 Hoffmann La Roche Cadenas ligeras comunes y procedimientos de uso
US10383929B2 (en) 2014-12-12 2019-08-20 Bluebird Bio, Inc. BCMA chimeric antigen receptors
GB201500461D0 (en) 2015-01-12 2015-02-25 Cresendo Biolog Ltd Therapeutic molecules
CR20170526A (es) 2015-05-20 2018-04-03 Janssen Biotech Inc ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38
EP3297672B1 (en) * 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
JOP20160154B1 (ar) 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
TWI811023B (zh) 2015-08-17 2023-08-01 美商健生生物科技公司 抗bcma抗體,結合bcma及cd3之雙特異性抗原結合分子及其用途
EP3374397A2 (en) 2015-11-10 2018-09-19 University Medical Center Hamburg - Eppendorf Antigen-binding polypeptides directed against cd38
JP2019506155A (ja) 2016-01-12 2019-03-07 クレッシェンド、バイオロジックス、リミテッドCrescendo Biologics Limited 治療分子
CN105968203A (zh) * 2016-02-03 2016-09-28 南昌大学 一种抗前列腺特异性膜抗原胞外区的单域重链抗体
UA126657C2 (uk) 2016-02-03 2023-01-11 Емджен Рісерч (Мюнік) Ґмбг ОДНОЛАНЦЮГОВА КОНСТРУКЦІЯ АНТИТІЛА ДО BCMA І CD3<font face="Symbol">e</font>
CN105968204B (zh) 2016-02-03 2020-01-21 中国人民解放军第三军医大学第一附属医院 一种抗前列腺特异性膜抗原的单域重链抗体
IL299221A (en) 2016-06-21 2023-02-01 Teneobio Inc Cd3 binding antibodies
CN109862784A (zh) 2016-08-24 2019-06-07 特尼奥生物股份有限公司 产生经修饰的仅有重链的抗体的转基因非人动物
CR20220578A (es) 2016-09-14 2023-01-17 Teneobio Inc Anticuerpos de unión a cd3
KR102275008B1 (ko) 2016-11-23 2021-07-13 하푼 테라퓨틱스, 인크. 전립선 특이 막 항원 결합 단백질
EP3559035A1 (en) 2016-12-21 2019-10-30 TeneoBio, Inc. Anti-bcma heavy chain-only antibodies
CN110891971B (zh) 2017-06-20 2024-01-12 特尼奥生物股份有限公司 仅有重链的抗bcma抗体
JP7240335B2 (ja) 2017-06-20 2023-03-15 テネオワン, インコーポレイテッド 抗bcma重鎖のみ抗体
WO2019000223A1 (en) 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
WO2019006072A1 (en) 2017-06-30 2019-01-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services CHIMERIC ANTIGENIC RECEPTORS TO ANTIGEN OF MATURATION OF LYMPHOCYTES B WITH HUMAN DOMAINS
GB201711068D0 (en) 2017-07-10 2017-08-23 Crescendo Biologics Ltd Therapeutic molecules binding PSMA
US20200207867A1 (en) 2017-09-13 2020-07-02 Teneobio, Inc. Heavy chain antibodies binding to ectoenzymes
CN111788225B (zh) 2017-10-10 2025-02-18 赛诺菲 抗cd38抗体及与抗cd3和抗cd28抗体的组合
EP3694553A4 (en) 2017-10-12 2021-08-11 Amphivena Therapeutics, Inc. CD3 BINDING PROTEIN DOSAGE SCHEDULE
EA202091557A1 (ru) 2017-12-22 2020-11-18 Тенеобио, Инк. Антитела, содержащие только тяжелые цепи, которые связываются с cd22
EP3732199A1 (en) 2017-12-27 2020-11-04 TeneoBio, Inc. Cd3-delta/epsilon heterodimer specific antibodies
BR112020023975A2 (pt) 2018-05-24 2021-02-23 Ayala Pharmaceuticals Inc. composições que compreendem os compostos de bisfluoroalquil-1,4-benzodiazepinona e imunoterapêuticos e métodos de uso das mesmas
LT3823990T (lt) 2018-07-20 2026-04-10 TeneoTwo, Inc. Antikūnai iš sunkiosios grandinės, besirišantys prie cd19
SG11202102713TA (en) 2018-09-21 2021-04-29 Teneobio Inc Methods for purifying heterodimeric, multispecific antibodies
WO2020087065A1 (en) 2018-10-26 2020-04-30 Teneobio, Inc. Heavy chain antibodies binding to cd38
CA3133654A1 (en) 2019-04-05 2020-10-08 Teneobio, Inc. Heavy chain antibodies binding to psma
CN114206927B (zh) 2019-06-14 2025-03-21 特尼奥生物股份有限公司 与cd22和cd3结合的多特异性重链抗体
BR112022011824A2 (pt) 2019-12-18 2022-08-30 Teneofour Inc Anticorpos de cadeia pesada que se ligam a cd38
KR20250007022A (ko) * 2020-04-29 2025-01-13 테네오원, 인코포레이티드 변형된 중쇄 불변 영역을 갖는 다중특이적 중쇄 항체
WO2021222616A1 (en) 2020-04-29 2021-11-04 Teneobio, Inc. Methods of treating multiple myeloma
CN116249548A (zh) 2020-05-11 2023-06-09 詹森生物科技公司 用于治疗多发性骨髓瘤的方法
IL299027A (en) 2020-06-30 2023-02-01 Teneobio Inc Multispecific antibodies that bind BCMA
TW202233684A (zh) 2020-11-18 2022-09-01 美商泰尼歐生物公司 結合於葉酸受體α之重鏈抗體
WO2022183074A2 (en) 2021-02-25 2022-09-01 Teneobio, Inc. Anti-psma antibodies and car-t structures
MX2023009882A (es) 2021-02-26 2023-08-30 Teneobio Inc Anticuerpos anti-muc1-c y estructuras car-t.
TW202304994A (zh) 2021-04-02 2023-02-01 美商泰尼歐生物公司 促效性抗il-2r抗體及使用方法
PE20260568A1 (es) 2021-04-06 2026-03-10 Teneobio Inc Anticuerpos anti-cd19 y estructuras car-t
CN117337303A (zh) 2021-04-16 2024-01-02 特尼奥生物股份有限公司 抗cd20抗体及car-t结构
WO2022271987A1 (en) 2021-06-23 2022-12-29 TeneoFour, Inc. Anti-cd38 antibodies and epitopes of same
WO2023004197A1 (en) 2021-07-23 2023-01-26 Teneoten, Inc. Heavy chain antibodies binding to hepatitis b surface antigen
US20240400716A1 (en) * 2021-11-09 2024-12-05 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Molecules that bind to prostate specific membrane antigen (psma) polypeptides
IL314993A (en) * 2022-02-23 2024-10-01 Xencor Inc Anti-cd28 x anti-psma antibodies
WO2023193015A1 (en) * 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies

Similar Documents

Publication Publication Date Title
Gebauer et al. Engineered protein scaffolds as next-generation therapeutics
JP4992068B2 (ja) 超高親和性中和抗体
KR102056932B1 (ko) 메디토프와 메디토프-결합 항체 및 이들의 용도
JP7116736B2 (ja) 操作されたヘテロ二量体タンパク質
US20210230269A1 (en) Immune-stimulating monoclonal antibodies against human interleukin-2
JP6494565B2 (ja) オリゴマー特異アミロイドベータエピトープおよび抗体
JP2021530236A5 (cg-RX-API-DMAC7.html)
JP6152090B2 (ja) 視神経脊髄炎を処置するための組成物および方法
CN102224168B (zh) 用于生产抗淀粉状蛋白β肽抗体的含有D-肽的组合物
JP2024507540A5 (cg-RX-API-DMAC7.html)
JP2022543070A5 (cg-RX-API-DMAC7.html)
JP5149269B2 (ja) 抗イディオタイプ抗体を得る方法
JP2022505445A5 (cg-RX-API-DMAC7.html)
US20120315270A1 (en) Rsv immunogens, antibodies and compositions thereof
US20190031770A1 (en) Intercalated single-chain variable fragments
CN119060177A (zh) 单结构域血清白蛋白结合蛋白质
JP2019503990A (ja) 改良された血清アルブミン結合剤
JP2005518454A (ja) 抗体アセンブリ単位を含むナノ構造
WO2019098763A9 (ko) 알파-시누클레인에 대한 항체 및 그 용도
JP2025512865A5 (cg-RX-API-DMAC7.html)
JP2023553694A5 (cg-RX-API-DMAC7.html)
TW202144433A (zh) 抗體或其抗原結合片段、其製備方法及醫藥用途
PT1817342E (pt) Método de purificação por afinidade
JP2025504537A (ja) Hbv感染及び関連疾患の治療のためのエピトープペプチド及び抗体
EP0957111B1 (en) Specific binding proteins for treating canine allergy